Fortis Technologies has published an application note showing the successful analysis of Tamiflu (oseltamivir) on its silica-based Fortis C18 column.
The official method approved by the Centre for Disease Control and Prevention (CDC) shows that the best option for the analysis of oseltamivir is by using high-pH mobile phase to neutralise the analyte.
A Fortis C18 column is used in this application due to its ability to work with high-pH mobile phase systems.
Based upon a silica particle template, the bonding process of Fortis C18 allows the full use of the pH range from 1-12 without the need for a hybrid technology.
Being able to operate on a silica particle means no loss of efficiency, loadability or speed of equilibration.
Scalability and ease of method transfer from UHPLC through to preparative chromatography is maintained in the simplest of fashions.
